Patents by Inventor David C. Litzinger

David C. Litzinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200362006
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: January 24, 2020
    Publication date: November 19, 2020
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
  • Publication number: 20190381093
    Abstract: This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.
    Type: Application
    Filed: July 19, 2017
    Publication date: December 19, 2019
    Inventors: Jack KESSLER, David C. LITZINGER, Christopher RHODES, Andrew M. CERRO
  • Publication number: 20180344813
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
    Type: Application
    Filed: June 9, 2016
    Publication date: December 6, 2018
    Inventors: Mary ERICKSON, David C. LITZINGER, Soumitra S. GHOSH, Zijian GUO, Manoj P. SAMANT, Abhinandini SHARMA, Lala MAMEDOVA, Odile Esther LEVY, Caroline EKBLAD
  • Publication number: 20180305430
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: January 29, 2018
    Publication date: October 25, 2018
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
  • Patent number: 9879063
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: January 30, 2018
    Assignee: Aegerion Pharmaceuticals, Inc.
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
  • Publication number: 20170114114
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Swetha Neravetla, Chengzao Sun, Manoj P. Samant, Odile E. Levy, Abhinandini Sharma, Lala Mamedova, Christopher Soares
  • Patent number: 9593154
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: March 14, 2017
    Assignees: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLC
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Swetha Neravetla, Chengzao Sun, Manoj P. Samant, Odile E. Levy, Abhinandini Sharma, Lala Mamedova, Christopher J. Soares
  • Publication number: 20160207974
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: August 27, 2015
    Publication date: July 21, 2016
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
  • Patent number: 9382304
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: July 5, 2016
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
  • Publication number: 20160137709
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: July 15, 2015
    Publication date: May 19, 2016
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
  • Patent number: 9260472
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: February 16, 2016
    Assignee: AMBRX, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. Dimarchi, Anna-Maria A. Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Patent number: 8907064
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: December 9, 2014
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Patent number: 8906676
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: December 9, 2014
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Publication number: 20140256621
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: July 3, 2012
    Publication date: September 11, 2014
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekbland, Jonathan David Roth
  • Publication number: 20140235535
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
    Type: Application
    Filed: July 3, 2012
    Publication date: August 21, 2014
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
  • Patent number: 8778880
    Abstract: Modified human growth hormone polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: July 15, 2014
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Publication number: 20130274182
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 17, 2013
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
  • Patent number: 8178494
    Abstract: Formulations of modified growth hormone polypeptides are provided, including human growth hormone polypeptides with one or more non-naturally encoded amino acids with an increased half-life.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: May 15, 2012
    Assignee: AMBRX, Inc.
    Inventors: Anna-Maria Hays, Ying Buechler, David C. Litzinger
  • Patent number: 8163695
    Abstract: Formulations of modified human growth hormone polypeptides are provided.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: April 24, 2012
    Assignee: Ambrx
    Inventors: Anna-Maria A. Hays, Ying Buechler, David C. Litzinger
  • Patent number: 8143216
    Abstract: Modified growth hormone polypeptide and uses thereof are provided.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: March 27, 2012
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria A. Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger